IL165394A0 - Use of thio-oxindole derivatives in treatment of skin disorders - Google Patents

Use of thio-oxindole derivatives in treatment of skin disorders

Info

Publication number
IL165394A0
IL165394A0 IL16539404A IL16539404A IL165394A0 IL 165394 A0 IL165394 A0 IL 165394A0 IL 16539404 A IL16539404 A IL 16539404A IL 16539404 A IL16539404 A IL 16539404A IL 165394 A0 IL165394 A0 IL 165394A0
Authority
IL
Israel
Prior art keywords
thio
treatment
skin disorders
oxindole derivatives
oxindole
Prior art date
Application number
IL16539404A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of IL165394A0 publication Critical patent/IL165394A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • A61Q7/02Preparations for inhibiting or slowing hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16539404A 2002-06-25 2004-11-25 Use of thio-oxindole derivatives in treatment of skin disorders IL165394A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39191302P 2002-06-25 2002-06-25
PCT/US2003/019791 WO2004000227A2 (fr) 2002-06-25 2003-06-23 Utilisation de derives de thio-oxindole dans le traitement de troubles cutanes

Publications (1)

Publication Number Publication Date
IL165394A0 true IL165394A0 (en) 2006-01-15

Family

ID=30000776

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16539404A IL165394A0 (en) 2002-06-25 2004-11-25 Use of thio-oxindole derivatives in treatment of skin disorders

Country Status (17)

Country Link
US (1) US7115649B2 (fr)
EP (1) EP1515680A4 (fr)
JP (1) JP2005535625A (fr)
KR (1) KR20050012831A (fr)
CN (1) CN1662206A (fr)
AR (1) AR040338A1 (fr)
AU (1) AU2003258952A1 (fr)
BR (1) BR0312092A (fr)
CA (1) CA2489810A1 (fr)
EC (1) ECSP055575A (fr)
IL (1) IL165394A0 (fr)
MX (1) MXPA04012418A (fr)
NO (1) NO20045215L (fr)
RU (1) RU2005101624A (fr)
TW (1) TW200401637A (fr)
WO (1) WO2004000227A2 (fr)
ZA (1) ZA200410401B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
TW200407124A (en) * 2002-06-25 2004-05-16 Wyeth Corp Use of thio-oxindole derivatives in treatment of hormone-related conditions
CA2561014C (fr) 2004-04-08 2013-09-10 Wyeth Derives thioamide utiles en tant que modulateurs des recepteurs de la progesterone
ATE409699T1 (de) * 2004-04-08 2008-10-15 Wyeth Corp Verfahren zur minimierung von thioamidverunreinigungen
CA2563063C (fr) * 2004-04-27 2014-06-03 Wyeth Purification de modulateurs de recepteur de progesterone
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
AR063280A1 (es) 2006-10-12 2009-01-21 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos
WO2008088771A2 (fr) * 2007-01-12 2008-07-24 Cornell Research Foundation, Inc. Adénylyl cyclases en tant que nouvelles cibles pour le traitement d'une infection par des pathogènes eucaryotes
CN101636157A (zh) * 2007-01-12 2010-01-27 康乃尔研究基金会有限公司 作为抗菌干预的新型靶的腺苷酰环化酶
CN105218565A (zh) 2008-10-17 2016-01-06 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
WO2010045197A1 (fr) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Composés spiro-oxindole et leur utilisation comme agents thérapeutiques
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
CN102753556B (zh) 2009-10-14 2015-05-13 泽农医药公司 螺-羟吲哚化合物的合成方法
NZ601667A (en) 2010-02-26 2014-10-31 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
KR101278271B1 (ko) * 2011-08-02 2013-06-25 충남대학교산학협력단 인돌린-2-티온 유사체를 함유한 미백용 조성물
WO2014025942A1 (fr) 2012-08-09 2014-02-13 Emory University Modulateurs de récepteur nmda et utilisations associées à ceux-ci
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US169198A (en) * 1875-10-26 Improvement in treating quicksilver-ore
US92711A (en) * 1869-07-20 e d w a r d s
WO1985000519A1 (fr) * 1983-07-29 1985-02-14 Duke University Procede de traitement de troubles lies aux androgenes
DE4335876A1 (de) * 1993-10-17 1995-04-20 Schering Ag Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
DE59913181D1 (de) * 1998-10-23 2006-04-27 Aventis Pharma Sa Zubereitungen zur topischen applikation von antiandrogen wirksamen substanzen
WO2000038519A1 (fr) * 1998-12-31 2000-07-06 Sugen, Inc. Composes 3-heteroarylidenyl-2-indolinone utilises pour modulation de l'activite de la proteine kinase et dans la chimiotherapie du cancer
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
EP1206761B1 (fr) 1999-08-26 2007-10-03 Automotive Systems Laboratory Inc. Capteur magnetique
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US7119207B2 (en) * 2000-04-10 2006-10-10 Pfizer Inc Benzoamide piperidine containing compounds and related compounds
OA12245A (en) 2000-04-10 2003-11-10 Pfizer Prod Inc Benzoamide piperidine compounds as substance P antagonists.
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
JP4976849B2 (ja) * 2004-07-12 2012-07-18 ローム株式会社 半導体発光素子

Also Published As

Publication number Publication date
BR0312092A (pt) 2005-03-22
WO2004000227A3 (fr) 2004-04-08
CN1662206A (zh) 2005-08-31
AR040338A1 (es) 2005-03-30
US20040006122A1 (en) 2004-01-08
EP1515680A4 (fr) 2005-09-21
ZA200410401B (en) 2006-05-31
US7115649B2 (en) 2006-10-03
TW200401637A (en) 2004-02-01
NO20045215L (no) 2005-03-17
JP2005535625A (ja) 2005-11-24
CA2489810A1 (fr) 2003-12-31
MXPA04012418A (es) 2005-04-19
ECSP055575A (es) 2005-04-18
AU2003258952A1 (en) 2004-01-06
EP1515680A2 (fr) 2005-03-23
WO2004000227A2 (fr) 2003-12-31
KR20050012831A (ko) 2005-02-02
RU2005101624A (ru) 2005-06-27

Similar Documents

Publication Publication Date Title
ZA200410401B (en) Use of thio-oxindole derivatives in treatment of skin disorders
AU2003286567A8 (en) Methods for the treatment of skin disorders
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
EP1641378A4 (fr) Methodes et dispositifs de traitement de lesions cutanees
IL173395A0 (en) Pyridazine derivatives and their use as therapeutic agents
PL1599467T3 (pl) Nowe pochodne cyjanopirydyny użyteczne w leczeniu raka i innych zaburzeń
HUP0401023A3 (en) Use of flibanserin in the treatment of sexual disorders
ZA200505272B (en) Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines
AU2003264282A1 (en) Phenethanolamine derivatives and their use in the treatment of respiratory diseases
IL166780A0 (en) Use of ikappab-kinase inhibitors in pain therapy
AU2003265225A8 (en) Preparations for topical skin use and treatment
IL165397A0 (en) Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders
GB0520687D0 (en) Skin treatment formulations
AU2003278775A8 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
EP1515725A4 (fr) Utilisation de derives de cyclothiocarbamate pour le traitement de pathologies d'origine hormonale
AU2003228819A8 (en) Combinations for the treatment of inflammatory skin disorders
ZA200410157B (en) Methods of treating gastrointestinal and genitorinary pain disorders using vanilafaxin and derivatives
EP1636160A4 (fr) Nouveaux agents therapeutiques permettant de traiter le cancer, les maladies metaboliques et les affections cutanees
IL166016A0 (en) Topical treatment of skin diseases
AU2003209150A8 (en) Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
GB0211295D0 (en) Treatment of pain
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
IL162941A0 (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
IL166062A0 (en) Compositions and methods for therapeutic treatment
AU2003251407A8 (en) Topical treatment for skin irritation